High Prevalence of Multidrug-resistant Klebsiella Pneumoniae in Elderly Patients With Community-acquired Pneumonia: Risk Factors and Clinical Implications

老年社区获得性肺炎患者中多重耐药肺炎克雷伯菌的高流行率:危险因素和临床意义

阅读:1

Abstract

BACKGROUND: Multidrug-resistant (MDR) Klebsiella pneumoniae is an emerging cause of severe pneumonia in Southeast Asia. However, data on MDR K. pneumoniae in elderly patients with community-acquired pneumonia (CAP) remain limited. OBJECTIVE: To determine MDR K. pneumoniae prevalence among elderly CAP patients, identify risk factors, and evaluate resistance to empiric antibiotics. METHODS: A prospective cohort study was conducted at a tertiary geriatric hospital in Vietnam from January 2023 to June 2024. We analyzed a subgroup of 181 patients aged ≥ 60 years with culture-confirmed K. pneumoniae CAP. RESULTS: The median age was 81 years. The prevalence of MDR K. pneumoniae was 26.5% (48/181). Resistance rates to first-line empiric agents were high: ciprofloxacin (50.6%), levofloxacin (30.0%), ceftazidime (38.7%), and ceftriaxone (31.1%). Amikacin remained highly effective (1.5% resistance). In univariable analysis, Chronic Obstructive Pulmonary Disease (COPD) (OR 2.16; 95% CI 1.03-4.53; p = 0.039), prior intravenous antibiotic use within 90 days (OR 3.32; 95% CI 1.49-7.42; p = 0.002), and hospitalization within the preceding 30 days (OR 2.28; 95% CI 0.99-5.21; p = 0.048) were associated with MDR K. pneumoniae. In the multivariable model, prior intravenous antibiotic use within 90 days (OR 3.00; 95% CI 1.32-6.80; p = 0.009) was identified as the independent risk factor for MDR acquisition. CONCLUSION: A substantial proportion of elderly CAP patients harbor MDR K. pneumoniae at admission. Given high resistance to fluoroquinolones and cephalosporins, empiric guidelines require re-evaluation for patients with recent intravenous antibiotic exposure.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。